You should contact your GP if: You have been found to have elevated B12 levels on blood tests, particularly if levels exceed 1000 ng/L (approximately 740 pmol/L, though laboratory reference ranges vary) and you are not taking high-dose supplements You develop new symptoms after starting B12 supplementation, including persistent skin rashes, significant gastrointestinal disturbance, or unexplained symptoms You have underlying liver disease, kidney problems, or blood disorders and are considering B12 supplementation You are taking B12 supplements without medical supervision and have not had your levels checked, particularly if taking doses exceeding 2000 micrograms daily You experience symptoms that might indicate underlying disease, such as unexplained weight loss, persistent fatigue, jaundice, or abdominal swelling Call 999 or go to A&E if you develop severe allergic reactions following B12 injections, including difficulty breathing, facial swelling, or widespread rash, as these may indicate anaphylaxis, though this is extremely rare

BPC-157 also exerts anti-inflammatory and antioxidative effects by regulating nitric oxide production, reducing cytokine activity (including TNF- and IL-6), and protecting endothelial function
This listing groups the retatrutide vial, bacteriostatic water, and graduated syringes together for laboratory handling
maintenance phase is the heavy draw 26 weeks 13 vials Standard Phase 2 duration 32 weeks 16 vials Phase 2 T2D study duration 68 weeks 30 vials REDEFINE 1 / REDEFINE 2 endpoint duration Peptide Vials (10 mg vial, 2.4 mg/week target) Each 10 mg vial covers about 4 weekly doses at 2.4 mg/week